Telomir Acquires TELI to Secure Global Telomir-1 Rights
MIAMI, FL, April 24, 2026 Telomir Pharmaceuticals has announced the successful completion of its acquisition of TELI Pharmaceuticals, securing...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development EMA FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
MIAMI, FL, April 24, 2026 Telomir Pharmaceuticals has announced the successful completion of its acquisition of TELI Pharmaceuticals, securing...
